These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23636176)

  • 21. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices.
    Pisoni RL; Bragg-Gresham JL; Fuller DS; Morgenstern H; Canaud B; Locatelli F; Li Y; Gillespie B; Wolfe RA; Port FK; Robinson BM
    Am J Kidney Dis; 2011 Feb; 57(2):266-75. PubMed ID: 21251541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E; Ofsthun N; Lazarus JM
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system.
    Robinson B; Fuller D; Zinsser D; Albert J; Gillespie B; Tentori F; Turenne M; Port F; Pisoni R
    Am J Kidney Dis; 2011 Jun; 57(6):822-31. PubMed ID: 21530036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
    Spiegel DM; Khan I; Krishnan M; Mayne TJ
    Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005.
    Mau LW; Liu J; Qiu Y; Guo H; Ishani A; Arneson TJ; Gilbertson DT; Dunning SC; Collins AJ
    Am J Kidney Dis; 2010 Mar; 55(3):549-57. PubMed ID: 20116913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost savings using a protocol approach to manage anemia in a hemodialysis unit.
    Charlesworth EC; Richardson RM; Battistella M
    Am J Nephrol; 2014; 39(6):509-14. PubMed ID: 24903565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of reimbursement of dialysis patients' transport expenses in Lorraine].
    Allenbach D; Pereira O
    Sante Publique; 2015; 27(1 Suppl):S155-65. PubMed ID: 26168629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reimbursement of dialysis: a comparison of seven countries.
    Vanholder R; Davenport A; Hannedouche T; Kooman J; Kribben A; Lameire N; Lonnemann G; Magner P; Mendelssohn D; Saggi SJ; Shaffer RN; Moe SM; Van Biesen W; van der Sande F; Mehrotra R;
    J Am Soc Nephrol; 2012 Aug; 23(8):1291-8. PubMed ID: 22677554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data.
    Malyszko J; Drozdz M; Zolkiewicz A; Rutkowski B
    Kidney Blood Press Res; 2012; 35(1):58-67. PubMed ID: 21876362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 35. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dialysis fluid endotoxin level and mortality in maintenance hemodialysis: a nationwide cohort study.
    Hasegawa T; Nakai S; Masakane I; Watanabe Y; Iseki K; Tsubakihara Y; Akizawa T
    Am J Kidney Dis; 2015 Jun; 65(6):899-904. PubMed ID: 25641063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
    Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
    Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in anemia management in US hemodialysis patients 2004-2010.
    Miskulin DC; Zhou J; Tangri N; Bandeen-Roche K; Cook C; Ephraim PL; Crews DC; Scialla JJ; Sozio SM; Shafi T; Jaar BG; Boulware LE;
    BMC Nephrol; 2013 Dec; 14():264. PubMed ID: 24289058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.